Accenture invests in AI infrastructure firm Iridius

Accenture, through its venture capital arm, has invested in Iridius, a Seattle-based enterprise AI infrastructure company focusing on regulated industries such as life sciences and pharmaceuticals.

As part of the investment – for which financial terms were not disclosed – Accenture and Iridius will also form a strategic partnership that helps life sciences firms scale AI adoption while ensure compliance, traceability, and auditability.

The partnership combines Accenture’s industry expertise and delivery scale with Iridius’ AI-powered regulatory and compliance capabilities. The partners will together build end-to-end compliance workflows across the value chain – from regulatory submissions and pharmacovigilance to clinical and manufacturing operations – and help life sciences firms speed up clinical timelines and reduce manual compliance work.

While AI can help life sciences firms accelerate new treatments, AI adoption still requires adherence to rigorous frameworks for patient safety and data integrity, as well as the maintenance of traceability and transparency.

“Our investment in Iridius is about giving life sciences organizations the ability to innovate without hesitation,” said Ray Pressburger, global life sciences lead at Accenture. “By embedding compliance into the core of AI, we’re helping accelerate clinical development, improve decision-making, and bring therapies to patients faster, all while meeting the rigorous expectations of regulators worldwide.”

Iridius was founded in 2024 and has six employees and eight advisors, according to its website. The startup’s proprietary technology includes a knowledge engine that translates regulatory standards and procedures into structured, machine-readable logic. The firm also has an intelligence solution factory that helps create compliant workflows across the pharma value chain.

“Together, we’re helping customers reimagine complex workflows with AI, turning it from a risk to manage into a trusted capability that strengthens compliance, enables innovation with confidence, and makes compliance a strategic advantage,” said Mike Kropp, co-founder and CEO of Iridius.

Accenture also recently invested in General Robotics, a Redmond, WA-based artificial intelligence research and deployment company.